Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Firmonertinib Combined With Bevacizumab as Neoadjuvant Therapy in Stage II-IIIB, Resectable, EGFR-mutated Non-small Cell Lung Cancer Patients: A Single-arm, Multi-center, Open-label Phase II Clinical Study

NCT07182708 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07182708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07182708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Firmonertinib Combined With Bevacizumab as Neoadjuvant Therapy in Stage II-IIIB, Resectable, EGFR-mutated Non-small Cell Lung Cancer Patients: A Single-arm, Multi-center, Open-label Phase II Clinical Study
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
June 30, 2030
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, nsclc (non-small cell lung cancer), resectable lung non-small cell carcinoma